The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
IMCD expects operating EBITA growth in 2021
The agreement also includes tolling and service agreements between Solvay and OpenGate to ensure a seamless transition and minimal customer disruption.
The facility will recycle textile waste, including items such as worn-out jeans and production scraps, to manufacture 60,000 metric tons of Circulose dissolving pulp per year
Sales grew by 14% to a Q1 record-high of $1,109 million, driven by continued robust 15% volume growth
Q1 synergy-driven sales grew 45 percent year on year
Led by Key Partners Capital with participation from Astanor Ventures, Horizons Ventures and Cape Capital, the Series C cements Modern Meadow as a leader in biofabrication
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
The company has posted net profit of Rs.155.85 crores for the period ended March 31, 2021
During the three months ended March 31, 2021, the company spent $98 million on capital expenditures as compared to $61 million in the same period of 2020
With no significant planned maintenance for our assets during the second quarter, we plan to operate at nearly full capacity worldwide to meet robust demand
The company posted net profit of Rs.175.05 crores for the period ended March 31, 2021
WACKER performed very well in Q1 2021
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
Completed a planned turnaround at the Geismar 2 plant and expects to complete the Geismar 2 debottlenecking project by mid-2021.
Acquisition will enable accelerated growth of key animal nutrition markets
Sales revenue from chemical intermediates increased 2% driven by a 14% increase in selling prices
EBITDA of CHF 164 million rose by 4 % in Swiss francs, generating a notably improved EBITDA margin at 16.4 % (vs. 15.4 %)
Subscribe to our newsletter & stay updated.
_IndianOil_256_275.jpg)
